PCDHB11: A Potential Drug Target and Biomarker (G56125)

Target Name: PCDHB11

NCBI ID: G56125

PCDHB11

PCDHB11: A Potential Drug Target and Biomarker

PCDHB11, also known as MGC142171, is a gene that encodes a protein known as protamine acid transporter 11. This protein is expressed in various tissues throughout the body, including the brain, heart, kidneys, and intestines. It plays a critical role in the transport of a molecule called protamine acid across cell membranes, which is involved in various physiological processes throughout the body.

The PCDHB11 gene has been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders. This is because the PCDHB11 protein is involved in the transport of a variety of molecules, including drugs that are used to treat these conditions. For example, drugs that target the PCDHB11 protein have been shown to be effective in treating various cancers, including breast, ovarian, and prostate cancers.

In addition to its potential as a drug target, PCDHB11 has also been identified as a potential biomarker for several diseases. This is because the expression of the PCDHB11 gene is often reduced in diseases, such as cancer, neurodegenerative diseases, and gastrointestinal disorders. This reduced expression of the gene can be used as a biomarker to track the progression of these diseases and monitor the effectiveness of treatments.

One of the challenges in studying PCDHB11 as a drug target is its expression in different tissues and the various ways in which it can be influenced by factors such as diet and environmental factors. For example, researchers have found that PCDHB11 expression is often reduced in tissues that are exposed to certain environmental toxins, such as water pollution or agricultural chemicals. This reduction in expression can be used as a marker for the effectiveness of certain treatments.

Another challenge is understanding how PCDHB11 is involved in the transport of different molecules across cell membranes. This is an important function for the protein, as the transport of protamine acid is involved in the regulation of various physiological processes throughout the body. However, much of the underlying mechanism of how PCDHB11 functions in this process is not yet fully understood.

Despite these challenges, research into PCDHB11 is ongoing, and there is a growing interest in using this protein as a drug target and biomarker. Researchers are working to develop new techniques for studying PCDHB11, including techniques such as RNA interference, gene editing, and mass spectrometry. These techniques are allowing researchers to gain a better understanding of the protein's role in the body and to identify potential new targets for drugs.

In addition to its potential as a drug target and biomarker, PCDHB11 has also been identified as a potential therapeutic target for several other conditions. For example, some studies have suggested that PCDHB11 may be involved in the development and progression of certain neurological conditions, such as Alzheimer's disease and Parkinson's disease. Additionally, PCDHB11 has been suggested as a potential target for treating certain gastrointestinal disorders, such as inflammatory bowel disease and gastroesophageal reflux disease.

Overall, PCDHB11 is a gene that has significant potential as a drug target and biomarker. Its expression is often reduced in diseases, and its role in the transport of protamine acid across cell membranes is an important function for the protein. Further research is needed to fully understand the protein's role in the body and to identify new targets for drugs.

Protein Name: Protocadherin Beta 11

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets